EP1455812A4 - Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment - Google Patents
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatmentInfo
- Publication number
- EP1455812A4 EP1455812A4 EP02784651A EP02784651A EP1455812A4 EP 1455812 A4 EP1455812 A4 EP 1455812A4 EP 02784651 A EP02784651 A EP 02784651A EP 02784651 A EP02784651 A EP 02784651A EP 1455812 A4 EP1455812 A4 EP 1455812A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- monoclonal antibody
- multiple sclerosis
- antibody therapy
- antagonist anti
- sclerosis treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33335501P | 2001-11-26 | 2001-11-26 | |
US333355P | 2001-11-26 | ||
PCT/US2002/038164 WO2003045978A2 (en) | 2001-11-26 | 2002-11-26 | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1455812A2 EP1455812A2 (en) | 2004-09-15 |
EP1455812A4 true EP1455812A4 (en) | 2006-03-22 |
Family
ID=23302439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02784651A Withdrawn EP1455812A4 (en) | 2001-11-26 | 2002-11-26 | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1455812A4 (en) |
JP (1) | JP2005510570A (en) |
AU (1) | AU2002346581A1 (en) |
CA (1) | CA2466931A1 (en) |
WO (1) | WO2003045978A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
PL1682178T3 (en) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Methods of therapy for cancers expressing the cd40 antigen |
JP2009517339A (en) | 2005-11-01 | 2009-04-30 | ノバルティス アーゲー | Use of anti-CD40 antibodies |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
CN102585011A (en) * | 2012-02-10 | 2012-07-18 | 中国农业大学 | Preparation method for dog alpha interferon derivative and application |
KR20210035805A (en) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Increased immune activity through regulation of postcellular signaling factors |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
JP2021169423A (en) * | 2020-04-15 | 2021-10-28 | 洋悦 松川 | Method for administering pharmaceutical preparation |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
US20220233690A1 (en) | 2021-01-28 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037870A1 (en) * | 1999-11-25 | 2001-05-31 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases by an agonistic cd40-binding protein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
-
2002
- 2002-11-26 WO PCT/US2002/038164 patent/WO2003045978A2/en active Application Filing
- 2002-11-26 CA CA002466931A patent/CA2466931A1/en not_active Abandoned
- 2002-11-26 EP EP02784651A patent/EP1455812A4/en not_active Withdrawn
- 2002-11-26 JP JP2003547427A patent/JP2005510570A/en not_active Withdrawn
- 2002-11-26 AU AU2002346581A patent/AU2002346581A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037870A1 (en) * | 1999-11-25 | 2001-05-31 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases by an agonistic cd40-binding protein |
Non-Patent Citations (4)
Title |
---|
COMABELLA MANUEL ET AL: "Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients", JOURNAL OF NEUROIMMUNOLOGY, vol. 126, no. 1-2, May 2002 (2002-05-01), pages 205 - 212, XP002364117, ISSN: 0165-5728 * |
GERRITSE K ET AL: "CD40-CD40 LIGAND INTERACTIONS IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 6, 19 March 1996 (1996-03-19), pages 2499 - 2504, XP002013404, ISSN: 0027-8424 * |
JEFFERY D R: "Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis.", JOURNAL OF THE NEUROLOGICAL SCIENCES. 1 SEP 2000, vol. 178, no. 1, 1 September 2000 (2000-09-01), pages 2 - 9, XP002220791, ISSN: 0022-510X * |
MAURI CLAUDIA ET AL: "Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 6, June 2000 (2000-06-01), pages 673 - 679, XP002157458, ISSN: 1078-8956 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002346581A1 (en) | 2003-06-10 |
WO2003045978A3 (en) | 2003-07-31 |
WO2003045978A2 (en) | 2003-06-05 |
CA2466931A1 (en) | 2003-06-05 |
AU2002346581A8 (en) | 2003-06-10 |
JP2005510570A (en) | 2005-04-21 |
EP1455812A2 (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1391464A4 (en) | Anti-cd40 monoclonal antibody | |
TWI367102B (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
IL158831A0 (en) | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES | |
AU2002251562A1 (en) | Anti-CD40 monoclonal antibody | |
IL166244A0 (en) | Super humanized antibodies | |
IL200604A0 (en) | Human monoclonal antibodies against cd30 | |
IL149701A0 (en) | Use of anti-ctla-4 antibodies | |
EP1482972A4 (en) | Treatment of immunological disorders using anti-cd30 antibodies | |
AU1174702A (en) | Humanized anti-lt-beta-r antibodies | |
AU2002340139A1 (en) | Inhibitors of the egf receptor for the treatment of thyroid cancer | |
AU2002346581A8 (en) | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment | |
AU2003277832A8 (en) | Humanized tissue factor antibodies | |
AU2001255537A1 (en) | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | |
EP1435979A4 (en) | Methods for treating multiple sclerosis | |
AU2002360696A8 (en) | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis | |
EP1393746A4 (en) | Human polyclonal antibody compositions | |
EP1446416A4 (en) | Tumor specific monoclonal antibodies | |
TW517526U (en) | Structure of plate for trapping mouse | |
GB0121727D0 (en) | Monoclonal antibodies | |
GB0104244D0 (en) | Marker for antibody therapy | |
EP1595959A4 (en) | Method for enhancing efficacy of preparation of monoclonal antibody | |
GB0016824D0 (en) | Human monoclonal antibodies | |
GB0017139D0 (en) | Human monoclonal antibodies | |
SI2149585T1 (en) | Use of antagonistic anti-CD40 monoclonal antibodies | |
ME01876B (en) | Use of antagonistic anti-cd40 monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040604 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060208 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091110 |